GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Debt-to-Revenue

BioStem Technologies (BioStem Technologies) Debt-to-Revenue : 0.42 (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BioStem Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.61 Mil. BioStem Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.41 Mil. BioStem Technologies's annualized Revenue for the quarter that ended in Sep. 2023 was $14.40 Mil. BioStem Technologies's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 0.42.


BioStem Technologies Debt-to-Revenue Historical Data

The historical data trend for BioStem Technologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies Debt-to-Revenue Chart

BioStem Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.11 1.95 2.23 1.11 0.74

BioStem Technologies Quarterly Data
Sep15 Dec15 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.60 2.18 0.42

Competitive Comparison of BioStem Technologies's Debt-to-Revenue

For the Biotechnology subindustry, BioStem Technologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Debt-to-Revenue falls into.



BioStem Technologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BioStem Technologies's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.051 + 1.038) / 6.875
=0.74

BioStem Technologies's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.613 + 1.41) / 14.396
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.


BioStem Technologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BioStem Technologies (BioStem Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.